How is tirzepatide dosed, and how many units is a dose?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds Tirzepatide and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
The US tirzepatide labels start at 2.5 mg once weekly: Zepbound goes to 5 mg after 4 weeks and then may be increased in 2.5 mg increments after at least 4 weeks on the current dose, Mounjaro adds 2.5 mg increments after at least 4 weeks if additional glycemic control is needed, and both give a maximum of 15 mg in adults.12
The guide's example
2.5 mg of Tirzepatide from a 10 mg vial mixed with 1 mL is 25 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water | 3 mL of water |
|---|---|---|---|
| 10 mg30% set up12 | 10 mg/mL: 2.5 mg is 25 units, 5 mg is 50 units, 7.5 mg is 75 units, 10 mg is 100 units | 5 mg/mL: 2.5 mg is 50 units, 5 mg is 100 units, 7.5 mg is over 1 mL, 10 mg is over 1 mL | 3.333 mg/mL: 2.5 mg is 75 units, 5 mg is over 1 mL, 7.5 mg is over 1 mL, 10 mg is over 1 mL |
| 20 mg14% set up12 | 20 mg/mL: 2.5 mg is 12.5 units, 5 mg is 25 units, 7.5 mg is 37.5 units, 10 mg is 50 units | 10 mg/mL: 2.5 mg is 25 units, 5 mg is 50 units, 7.5 mg is 75 units, 10 mg is 100 units | 6.667 mg/mL: 2.5 mg is 37.5 units, 5 mg is 75 units, 7.5 mg is over 1 mL, 10 mg is over 1 mL |
| 30 mg23% set up12 | 30 mg/mL: 2.5 mg is 8.3 units, 5 mg is 16.7 units, 7.5 mg is 25 units, 10 mg is 33.3 units | 15 mg/mL: 2.5 mg is 16.7 units, 5 mg is 33.3 units, 7.5 mg is 50 units, 10 mg is 66.7 units | 10 mg/mL: 2.5 mg is 25 units, 5 mg is 50 units, 7.5 mg is 75 units, 10 mg is 100 units |
| 60 mg9% set up12 | 60 mg/mL: 2.5 mg is 4.2 units, 5 mg is 8.3 units, 7.5 mg is 12.5 units, 10 mg is 16.7 units | 30 mg/mL: 2.5 mg is 8.3 units, 5 mg is 16.7 units, 7.5 mg is 25 units, 10 mg is 33.3 units | 20 mg/mL: 2.5 mg is 12.5 units, 5 mg is 25 units, 7.5 mg is 37.5 units, 10 mg is 50 units |
Most often logged by Milligram users: 2.5 mg, 24% logged.12
How many units is a tirzepatide dose?
| Label product | Strength | Volume per dose |
|---|---|---|
| Single-dose pen or vial2 | 2.5 mg to 15 mg per 0.5 mL | 0.5 mL |
| Multi-dose vial, 10 mg or 20 mg in 2.4 mL1 | 4.17 mg/mL or 8.33 mg/mL | 0.6 mL (2.5 mg or 5 mg) |
| Multi-dose vial, 30 mg to 60 mg in 2.4 mL2 | 12.5 mg/mL to 25 mg/mL | 0.6 mL (7.5 mg to 15 mg) |
The labels give each dose as a volume, 0.5 mL or 0.6 mL, measured with a syringe such as a 1 mL syringe, and give no figure in units.2
Of the people who logged tirzepatide, 30% set up a 10 mg vial, 23% a 30 mg vial, 14% a 20 mg vial and 9% a 60 mg vial, and 12% set up a 10 mg vial with 1 mL of water; these are set-ups in the app, while the label's multi-dose vials are 2.4 mL of solution.1212 The labels give no water type or volume for a powder, and neither does the registry record of a Lilly phase 1 study in healthy participants (NCT03375463, "A Study of Tirzepatide (LY3298176) in Healthy Participants", 52 enrolled across all parts), whose Part A compared a tirzepatide solution with a powder mixed with water.3
2.5 mg of Tirzepatide from a 10 mg vial mixed with 1 mL is 25 units on a U-100 syringe.
12% set up 10 mg + 1 mL12
In an alert on dosing errors with compounded semaglutide, the FDA describes a U-100 (1 milliliter) insulin syringe on which a 5-unit dose is 0.05 milliliter.4
What the labels and trials give
The Zepbound label (to reduce excess body weight and maintain weight reduction in adults with obesity, or overweight with a weight-related comorbid condition, and moderate to severe obstructive sleep apnea in adults with obesity) gives 2.5 mg once weekly for 4 weeks for all indications, then 5 mg once weekly, after which the dosage may be increased in 2.5 mg increments after at least 4 weeks on the current dose.2 The Zepbound label gives the abdomen, the thigh or, when given by someone else, the back of the upper arm as subcutaneous sites, rotated with each dose.2
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| SURMOUNT-1 (Jastreboff and colleagues, 2022) | Double blind, subcutaneous once weekly: tirzepatide or placebo; tirzepatide arms started at 2.5 mg and rose 2.5 mg every 4 weeks to 5 mg, 10 mg or 15 mg56 | 2539 adults with a BMI of 30 or more, or 27 or more with a weight-related complication, excluding diabetes | 72 weeks, 20-week escalation |
| SURPASS-1 (Rosenstock and colleagues, 2021) | Double blind, once weekly: tirzepatide 5 mg, 10 mg or 15 mg, or placebo7 | 478 adults with type 2 diabetes controlled inadequately by diet and exercise | 40 weeks |
How tirzepatide is stored
The Mounjaro label says single-dose pens and vials are stored refrigerated at 2°C to 8°C in the original carton, and if needed can be kept at up to 30°C for a total of 21 days, then thrown away.1 The label says an in-use multi-dose vial is kept at 2°C to 8°C or at up to 30°C, and thrown away after 30 days at room temperature, 30 days after first use or 4 weekly doses.1 For a multi-dose vial not yet in use the label gives 2°C to 8°C, and says it is thrown away after 30 days at room temperature, up to 30°C.1 A letter in Diabetes Obesity Cardiometabolic CARE, "Weighing the Risks and Benefits of Microdosing Tirzepatide Vials", says single-dose vials carry uncertainty about peptide stability and product integrity after repeated entry, and that contamination and bacterial growth are possible.8 For compounded GLP-1 vials holding multiple doses, the FDA generally recommends that multi-dose vials of sterile medications be used within 28 days after first use, for contamination risk; the Mounjaro label gives its own in-use multi-dose vial 30 days after first use.91
Frequently asked questions
What if a tirzepatide dose is missed?
The Zepbound label says to give a missed dose as soon as possible within 4 days (96 hours), and otherwise to skip it.2
Is there a tirzepatide tablet or pill?
Can a pen's solution be moved to a syringe or split?
The Zepbound KwikPen instructions say not to transfer the medicine into a syringe, and to throw the pen away after 4 doses.2 A review in Obesity (Silver Spring), "Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi-Dose Pens", reports that labeling says not to transfer the pen's solution to a syringe, use it after four doses or split it into smaller doses, and that microdosing it is not endorsed by the manufacturer or approved by any regulatory agency.11
- Tirzepatide calculatorVial, water and dose to syringe units.
- Mixing guideThe general steps for mixing a vial.
- TirzepatideHalf-life, trials and labels.
- GLP-1 and incretin compoundsThe group tirzepatide belongs to.
- Semaglutide dosageLabel and logged doses.
- Retatrutide dosageLogged doses.
- Retatrutide vs tirzepatideA side-by-side comparison.
- GLP-1 dose conversionMoving between GLP-1 drugs.
- GLP-1 weight loss plateauWhy weight loss stalls on GLP-1 drugs.
How the logged figures are counted
Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.
References
- Eli Lilly and Company, via DailyMed (US National Library of Medicine). MOUNJARO (tirzepatide) injection, prescribing information (DailyMed, published 2 Sep 2026). 2026. dailymed.nlm.nih.gov
- Eli Lilly and Company, via DailyMed (US National Library of Medicine). ZEPBOUND (tirzepatide) injection, prescribing information (DailyMed, published 2 Sep 2026). 2026. dailymed.nlm.nih.gov
- ClinicalTrials.gov (US National Library of Medicine). ClinicalTrials.gov NCT03375463 (tirzepatide in healthy participants, solution against lyophilized powder). 2026. clinicaltrials.gov
- US Food and Drug Administration. FDA alerts of dosing errors associated with compounded injectable semaglutide products. 2026. fda.gov
- New England Journal of Medicine, via PubMed. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), PubMed abstract. 2022. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov (US National Library of Medicine). ClinicalTrials.gov NCT04184622 (SURMOUNT-1 registry record). 2026. clinicaltrials.gov
- The Lancet, via PubMed. Efficacy and safety of tirzepatide in patients with type 2 diabetes (SURPASS-1), PubMed abstract. 2021. pubmed.ncbi.nlm.nih.gov
- Diabetes Obesity Cardiometabolic CARE (American Diabetes Association), via PubMed Central. Weighing the Risks and Benefits of Microdosing Tirzepatide Vials. 2026. pmc.ncbi.nlm.nih.gov
- US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 10/01/2026). 2026. fda.gov
- DailyMed (US National Library of Medicine). DailyMed label search results for the drug name tirzepatide. 2026. dailymed.nlm.nih.gov
- Obesity (Silver Spring), via PubMed Central. Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi-Dose Pens. 2026. pmc.ncbi.nlm.nih.gov
- Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted